Friday, July 10, 2026
🇺🇸 FDA

pharma · Asthma · Respiratory Syncytial Virus Infections

GSK Glaxo Smith

GlaxoSmithKline

GSK Glaxo Smith drug portfolio — 194 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
Employees
30
Programs
205
Drugs
194
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Drug Pipeline

GSK Glaxo Smith pipeline

Portfolio lens on 194 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

GSK Glaxo Smith drug portfolio — 194 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

194 compounds

  1. a/vietnam/1194/2004

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  3. acetaminophen

    US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Cyclooxygenase inhibitor

  4. acyclovir sodium

    US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.

    Target
    DNA polymerase catalytic subunit
    Mechanism
    Human herpesvirus 1 DNA polymerase inhibitor

  5. adalimumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  6. adefovir dipivoxil

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.

    Target
    DNA polymerase/reverse transcriptase
    Mechanism
    DNA polymerase/reverse transcriptase inhibitor

  7. administered

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  8. albiglutide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.

    Target
    Glucagon-like peptide 1 receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  9. albuterol

    US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.

    Target
    Beta-2 adrenergic receptor
    Mechanism
    Beta-2 adrenergic receptor agonist

  10. albuterol sulfate

    US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.

    Target
    Beta-2 adrenergic receptor
    Mechanism
    Beta-2 adrenergic receptor agonist

  11. alcohol

    US regulatory status: approved.

  12. aldesleukin

    US regulatory status: approved. Molecular target: Interleukin-2 receptor.

    Target
    Interleukin-2 receptor
    Mechanism
    Interleukin-2 receptor agonist

  14. alosetron hydrochloride

    US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.

    Target
    5-hydroxytryptamine receptor 3A
    Mechanism
    Serotonin 3a (5-HT3a) receptor antagonist

  15. alzheimer

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  18. amoxicillin

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  19. antazoline phosphate

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  20. anti-

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  21. anti-melanoma mab fragments

    Various (V09)

    Various (V09) compound in GSK Glaxo Smith's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  22. antibiotics

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  23. apatinib

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  24. aprepitant

    Alimentary tract and metabolism (A04)

    US regulatory status: approved. Molecular target: Substance-P receptor.

    Target
    Substance-P receptor
    Mechanism
    Neurokinin 1 receptor antagonist

  25. asenapine

    Nervous system (N05)

    US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.

    Mechanism
    Serotonin 2a (5-HT2a) receptor antagonist

  26. aspirin

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  28. barium sulfate

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  29. belantamab mafodotin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tumor necrosis factor receptor superfamily member 17 binding agent

  30. belantamab mafodotin-blmf

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  31. belimumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 13B.

    Target
    Tumor necrosis factor ligand superfamily member 13B
    Mechanism
    Tumor necrosis factor ligand superfamily member 13B inhibitor

  32. benralizumab

    Respiratory system (R03)

    US regulatory status: approved. Molecular target: Interleukin-5 receptor subunit alpha.

    Target
    Interleukin-5 receptor subunit alpha
    Mechanism
    Interleukin-5 receptor subunit alpha inhibitor

  33. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  34. biological

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  35. bortezomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  36. budesonide

    Alimentary tract and metabolism (A07)

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  37. calcium

    US regulatory status: approved.

  38. capecitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  39. capsule

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  40. capsules

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  41. carbamazepine

    US regulatory status: approved. Molecular target: Sodium channel alpha subunit.

    Target
    Sodium channel alpha subunit
    Mechanism
    Sodium channel alpha subunit blocker

  42. carboplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  43. carfilzomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  44. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  46. chloride

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  47. chloroquine hydrochloride

    US regulatory status: approved. Molecular target: Ferriprotoporphyrin IX.

    Target
    Ferriprotoporphyrin IX
    Mechanism
    Ferriprotoporphyrin IX binding agent

  48. ciprofloxacin

    US regulatory status: approved. Molecular target: Bacterial DNA gyrase.

    Target
    Bacterial DNA gyrase
    Mechanism
    Bacterial DNA gyrase inhibitor

  49. cisplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  50. clobazam

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive allosteric modulator

  51. combination

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  53. control

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  54. covid-19 mrna vaccine

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Molecular target: Spike glycoprotein.

    Target
    Spike glycoprotein
    Mechanism
    Spike glycoprotein vaccine antigen

  55. dabrafenib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Mechanism: Serine/threonine-protein kinase B-raf inhibitor.

    Mechanism
    Serine/threonine-protein kinase B-raf inhibitor

  56. daprodustat

    Blood and blood forming organs (B03)

    US regulatory status: approved. Molecular target: Hypoxia-inducible factor prolyl hydroxylase.

    Target
    Hypoxia-inducible factor prolyl hydroxylase
    Mechanism
    Hypoxia-inducible factor prolyl hydroxylase inhibitor

  57. daratumumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  58. denosumab

    Musculo-skeletal system (M05)

    US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 11.

    Target
    Tumor necrosis factor ligand superfamily member 11
    Mechanism
    Tumor necrosis factor ligand superfamily member 11 inhibitor

  59. depemokimab

    Respiratory system (R03)

    Respiratory system (R03) compound in GSK Glaxo Smith's portfolio. Molecular target: Interleukin-5.

    Target
    Interleukin-5
    Mechanism
    Interleukin-5 inhibitor

  60. desonide

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  61. dexamethasone phosphate

    Systemic hormonal preparations (H02)

    Systemic hormonal preparations (H02) compound in GSK Glaxo Smith's portfolio.

  62. dexamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  66. dipivoxil

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  67. docetaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  68. dose

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  69. dose-escalation

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  70. dostarlimab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 antagonist

  72. dutasteride

    US regulatory status: approved. Molecular target: Steroid 5-alpha-reductase.

    Target
    Steroid 5-alpha-reductase
    Mechanism
    Steroid 5-alpha-reductase inhibitor

  74. eltrombopag

    Blood and blood forming organs (B02)

    US regulatory status: approved. Mechanism: Thrombopoietin receptor agonist.

    Mechanism
    Thrombopoietin receptor agonist

  75. enzalutamide

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  76. escalation

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  77. estropipate

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  78. expansion

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  79. extended-release

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  80. ezogabine

    US regulatory status: approved. Molecular target: KCNQ (Kv7) potassium channel.

    Target
    KCNQ (Kv7) potassium channel
    Mechanism
    KCNQ (Kv7) potassium channel opener

  81. florbetaben (18f)

    Various (V09)

    Various (V09) compound in GSK Glaxo Smith's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  82. florbetaben f-18

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  83. florbetapir f-18

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  84. fluorouracil

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  85. flutemetamol f-18

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  86. fluticasone

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  87. fluticasone furoate

    Respiratory system (R03)

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  90. fluticasone propionate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  92. formoterol

    Respiratory system (R03)

    Respiratory system (R03) compound in GSK Glaxo Smith's portfolio. Mechanism: Beta-2 adrenergic receptor agonist.

    Mechanism
    Beta-2 adrenergic receptor agonist

  93. formulation

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  95. glargine

    Development asset linked to GSK Glaxo Smith in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  96. glipizide

    US regulatory status: approved. Molecular target: Sulfonylurea receptor 1, Kir6.2.

    Target
    Sulfonylurea receptor 1, Kir6.2
    Mechanism
    Sulfonylurea receptor 1, Kir6.2 blocker

  97. group

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  98. hema-

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  99. herpes zoster vaccine (recombinant, adjuvanted)

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Molecular target: Envelope glycoprotein E.

    Target
    Envelope glycoprotein E
    Mechanism
    Envelope glycoprotein E vaccine antigen

  102. hydromorphone

    Development asset linked to GSK Glaxo Smith in public FDA and regional records. Mechanism: Mu opioid receptor agonist.

    Mechanism
    Mu opioid receptor agonist

  103. inactivated

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  106. infusion

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  107. inhalation

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  108. injection

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  109. insulin

    Development asset linked to GSK Glaxo Smith in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  110. insulin glargine

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  111. intravenous

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  112. isatuximab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  113. lamivudine

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  114. lamotrigine

    US regulatory status: approved. Molecular target: Sodium channel alpha subunit.

    Target
    Sodium channel alpha subunit
    Mechanism
    Sodium channel alpha subunit blocker

  115. lapatinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Mechanism: Receptor protein-tyrosine kinase erbB-2 inhibitor.

    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  116. lenalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  117. levodopa + carbidopa

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  118. luspatercept

    Blood and blood forming organs (B03)

    Blood and blood forming organs (B03) compound in GSK Glaxo Smith's portfolio. Molecular target: Transforming growth factor beta.

    Target
    Transforming growth factor beta
    Mechanism
    Transforming growth factor beta inhibitor

  119. luspatercept-aamt

    US regulatory status: approved. Molecular target: Transforming growth factor beta.

    Target
    Transforming growth factor beta
    Mechanism
    Transforming growth factor beta inhibitor

  120. malathion

    US regulatory status: approved. Molecular target: Acetylcholinesterase.

    Target
    Acetylcholinesterase
    Mechanism
    Acetylcholinesterase inhibitor

  121. matching

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  122. meningococcal

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  125. mepolizumab

    Respiratory system (R03)

    US regulatory status: approved. Molecular target: Interleukin-5.

    Target
    Interleukin-5
    Mechanism
    Interleukin-5 inhibitor

  126. momelotinib

    Development asset linked to GSK Glaxo Smith in public FDA and regional records. Molecular target: Tyrosine-protein kinase JAK1.

    Target
    Tyrosine-protein kinase JAK1
    Mechanism
    Tyrosine-protein kinase JAK1 inhibitor

  127. monotherapy

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  128. montelukast

    Development asset linked to GSK Glaxo Smith in public FDA and regional records. Mechanism: Cysteinyl leukotriene receptor 1 antagonist.

    Mechanism
    Cysteinyl leukotriene receptor 1 antagonist

  129. mupirocin

    US regulatory status: approved. Molecular target: Isoleucine--tRNA ligase.

    Target
    Isoleucine--tRNA ligase
    Mechanism
    Isoleucyl-tRNA synthetase inhibitor

  131. nacl

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  132. niraparib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Molecular target: Poly [ADP-ribose] polymerase 2.

    Target
    Poly [ADP-ribose] polymerase 2
    Mechanism
    Poly [ADP-ribose] polymerase-1 inhibitor

  133. niraparib tosilate hydrate

    Development asset linked to GSK Glaxo Smith in public FDA and regional records. Molecular target: Poly [ADP-ribose] polymerase 2.

    Target
    Poly [ADP-ribose] polymerase 2
    Mechanism
    Poly [ADP-ribose] polymerase 2 inhibitor

  134. nirogacestat

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Molecular target: Gamma-secretase.

    Target
    Gamma-secretase
    Mechanism
    Gamma-secretase inhibitor

  135. normal

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  136. orlistat

    Alimentary tract and metabolism (A08)

    US regulatory status: approved. Molecular target: Gastric triacylglycerol lipase.

    Target
    Gastric triacylglycerol lipase
    Mechanism
    Pancreatic lipase inhibitor

  137. oxaliplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  139. pazopanib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.

    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  140. pembrolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  141. pemetrexed sodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  143. pioglitazone

    Alimentary tract and metabolism (A10)

    Alimentary tract and metabolism (A10) compound in GSK Glaxo Smith's portfolio. Mechanism: Peroxisome proliferator-activated receptor gamma agonist.

    Mechanism
    Peroxisome proliferator-activated receptor gamma agonist

  144. pioglitazone hydrochloride

    US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor gamma.

    Target
    Peroxisome proliferator-activated receptor gamma
    Mechanism
    Peroxisome proliferator-activated receptor gamma agonist

  145. placebo

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  146. pneumococcal

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  149. polidocanol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  150. poliorix

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  151. polysaccharide

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  152. pomalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  153. postoperative

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  154. powder

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  155. prednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  156. recombinant

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  159. regimen

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  160. retigabine

    Nervous system (N03)

    Nervous system (N03) compound in GSK Glaxo Smith's portfolio. Molecular target: KCNQ (Kv7) potassium channel.

    Target
    KCNQ (Kv7) potassium channel
    Mechanism
    KCNQ (Kv7) potassium channel opener

  161. rosiglitazone

    Alimentary tract and metabolism (A10)

    Alimentary tract and metabolism (A10) compound in GSK Glaxo Smith's portfolio. Molecular target: Peroxisome proliferator-activated receptor gamma.

    Target
    Peroxisome proliferator-activated receptor gamma
    Mechanism
    Peroxisome proliferator-activated receptor gamma agonist

  162. rotavirus vaccine

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response

  163. rotavirus vaccine, live

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response

  165. saline

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  166. salmeterol

    Respiratory system (R03)

    Respiratory system (R03) compound in GSK Glaxo Smith's portfolio. Mechanism: Beta-2 adrenergic receptor agonist.

    Mechanism
    Beta-2 adrenergic receptor agonist

  167. salmeterol product

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  168. shingles (herpes zoster) vaccine (live)

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response

  171. solution

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  172. solvent

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  173. spray

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  174. standard

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  175. stro-

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  176. subcutaneous

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  177. suspension

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  178. t-cell

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  179. tablet

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  180. tablets

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  182. tamsulosin

    Development asset linked to GSK Glaxo Smith in public FDA and regional records. Mechanism: Adrenergic receptor alpha-1 antagonist.

    Mechanism
    Adrenergic receptor alpha-1 antagonist

  184. therapy

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  185. topotecan

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Mechanism: DNA topoisomerase I, mitochondrial inhibitor.

    Mechanism
    DNA topoisomerase I, mitochondrial inhibitor

  186. topotecan hydrochloride

    US regulatory status: approved. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I, mitochondrial inhibitor

  187. treatment

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  188. ulipristal acetate

    Genito-urinary system and sex hormones (G03)

    US regulatory status: approved. Molecular target: Progesterone receptor.

    Target
    Progesterone receptor
    Mechanism
    Progesterone receptor modulator

  189. umeclidinium

    Respiratory system (R03)

    Respiratory system (R03) compound in GSK Glaxo Smith's portfolio. Mechanism: Muscarinic acetylcholine receptor M3 antagonist.

    Mechanism
    Muscarinic acetylcholine receptor M3 antagonist

  191. urea c-13

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  192. vaccine

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  193. varicella-

    Development asset linked to GSK Glaxo Smith in public FDA and regional records.

  194. zanamivir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Neuraminidase.

    Target
    Neuraminidase
    Mechanism
    Neuraminidase inhibitor

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.